RedHill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

by · The Cerbat Gem

RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the target of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 1,600 shares, a decrease of 78.4% from the October 15th total of 7,400 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 69,300 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on RedHill Biopharma in a research report on Saturday, August 24th. They set a “hold” rating on the stock.

Get Our Latest Analysis on RedHill Biopharma

RedHill Biopharma Trading Down 9.0 %

RDHL traded down $0.71 during trading hours on Tuesday, reaching $7.18. The company’s stock had a trading volume of 36,651 shares, compared to its average volume of 115,147. RedHill Biopharma has a fifty-two week low of $6.80 and a fifty-two week high of $82.00. The business’s 50-day moving average is $8.86 and its 200-day moving average is $154.21.

Institutional Trading of RedHill Biopharma

An institutional investor recently raised its position in RedHill Biopharma stock. Gagnon Securities LLC lifted its stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) by 32.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 118,360 shares of the biotechnology company’s stock after acquiring an additional 28,771 shares during the quarter. Gagnon Securities LLC owned 0.40% of RedHill Biopharma worth $63,000 as of its most recent filing with the Securities and Exchange Commission. 7.20% of the stock is owned by hedge funds and other institutional investors.

RedHill Biopharma Company Profile

(Get Free Report)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.

Recommended Stories